On August 19, Qingdao Municipal Party Secretary Zeng Zanrong visited Jimo District and Laoshan District to inspect and supervise the progress of key project construction, and also visited Qingdao Baheal Pharmaceutical for an inspection and guidance. Zheng Aiju, General Manager of Qingdao Baheal Pharmaceutical, accompanied him during the visit.

Zeng Zanrong visited the production workshops and supporting projects of Qingdao Baheal Pharmaceutical, listened to detailed introductions about the research and production of relevant pharmaceutical products, and highly commended the company's long-term focus on the research and development of high-end pharmaceutical formulations and its contributions to the development of Qingdao's life sciences and health industry. He also expressed hope that Qingdao Baheal Pharmaceutical would accelerate the production of pharmaceutical tablets, granules, and other products, continue to strengthen technological innovation, strive to launch more innovative drugs, expand market share, and continuously enhance the company's core competitiveness.

As the high-end controlled-release formulation R&D and production platform under Baheal Pharmaceutical, Qingdao Baheal Pharmaceutical has long focused on the R&D, production, and industrialization of osmotic pumps, micro-pellet coating, and skeletal tablets. It has repeatedly passed the U.S. FDA cGMP certification with “zero defects,” aligning its production system with international standards. Additionally, multiple products have achieved simultaneous production and sales in both China and the United States, with several high-end formulations in the metabolic disease field included in the national procurement and medical insurance directories, bringing high-quality medications of international standards to domestic patients.

In recent years, under the guidance of the group's innovation strategy, Qingdao Baheal Pharmaceutical is also transitioning toward becoming an innovative pharmaceutical company. By 2025, the third phase of Qingdao Baheal Pharmaceutical's construction project will be completed and put into use, with an additional production capacity of 5.6 billion tablets/capsules. The total area of the pharmaceutical plant will reach 85,600 square meters, further enhancing the company's production capacity and intelligent manufacturing capabilities.

Furthermore, Qingdao Baheal Pharmaceutical actively expands collaborations with research institutions and innovative pharmaceutical companies to support the research, development, and application of innovative drugs. The company's jointly developed anti-tuberculosis Class 1 new drug NTB-3119M with the Institute of Materia Medica, Chinese Academy of Medical Sciences, has entered the Phase I clinical trial stage, offering new treatment options for patients with drug-resistant tuberculosis. Furthermore, Qingdao Baheal Pharmaceutical will establish a high-standard, specialized production base for nuclear medicine-compatible cold medicine packaging, providing industrialization support for the group's domestically developed innovative nuclear medicine drug Jilenta.

In the future, Qingdao Baheal Pharmaceutical will leverage its dual advantages in technological innovation and industrial upgrading to continuously expand its business scale while providing robust support for drug development and industrialization for innovative pharmaceutical companies. This will drive the commercialization and application of more innovative drug products with independent intellectual property rights, offering patients better products and services.